Hyaluronic Acid Receptor-Mediated Nanomedicines and Targeted Therapy

被引:8
作者
Ouyang, Qiuhong [1 ,2 ]
Zhao, Ying [1 ,2 ]
Xu, Kunyao [3 ]
He, Yuechen [1 ,2 ]
Qin, Meng [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Preclin Safety Evaluat Drugs, Chengdu 610041, Peoples R China
[3] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing 100029, Peoples R China
来源
SMALL METHODS | 2024年 / 8卷 / 10期
关键词
hyaluronic acid; nanomedicines; receptor-targeted delivery; HEPATIC STELLATE CELLS; EXTRACELLULAR-MATRIX; KNEE OSTEOARTHRITIS; MOLECULAR-WEIGHT; DRUG-DELIVERY; NANOPARTICLES; CD44; PROGRESSION; INHIBITION; IMMUNE;
D O I
10.1002/smtd.202400513
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Hyaluronic acid (HA) is a naturally occurring polysaccharide found in the extracellular matrix with broad applications in disease treatment. HA possesses good biocompatibility, biodegradability, and the ability to interact with various cell surface receptors. Its wide range of molecular weights and modifiable chemical groups make it an effective drug carrier for drug delivery. Additionally, the overexpression of specific receptors for HA on cell surfaces in many disease states enhances the accumulation of drugs at pathological sites through receptor binding. In this review, the modification of HA with drugs, major receptor proteins, and the latest advances in receptor-targeted nano drug delivery systems (DDS) for the treatment of tumors and inflammatory diseases are summarized. Furthermore, the functions of HA with varying molecular weights of HA in vivo and the selection of drug delivery methods for different diseases are discussed. Hyaluronic acid with multiple modifying groups can be modified by different methods and assembled with drugs to form various types of nanomedicines. Through the targeted binding of HA to receptors overexpressed on the cell surface in inflammatory and tumor microenvironments, the drugs can be delivered precisely to the target site, improving therapeutic efficacy and in vivo safety. image
引用
收藏
页数:30
相关论文
共 203 条
  • [51] Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury
    Huang, Zhi-Wei
    Shi, Yannan
    Zhai, Yuan-Yuan
    Du, Chu-Chu
    Zhai, Jiaoyuan
    Yu, Run-Jie
    Kou, Longfa
    Xiao, Jian
    Zhao, Ying-Zheng
    Yao, Qing
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 334 : 275 - 289
  • [52] Hyaluronic acid in the treatment of dry eye disease
    Hynnekleiv, Leif
    Magno, Morten
    Vernhardsdottir, Ragnheidur R.
    Moschowits, Emily
    Tonseth, Kim Alexander
    Dartt, Darlene A.
    Vehof, Jelle
    Utheim, Tor P.
    [J]. ACTA OPHTHALMOLOGICA, 2022, 100 (08) : 844 - 860
  • [53] Mammalian hyaluronan synthases
    Itano, N
    Kimata, K
    [J]. IUBMB LIFE, 2002, 54 (04) : 195 - 199
  • [54] Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking
    Jackson, David G.
    [J]. MATRIX BIOLOGY, 2019, 78-79 : 219 - 235
  • [55] Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis
    Jauch, Anna Sophia
    Wohlfeil, Sebastian A.
    Weller, Celine
    Dietsch, Bianca
    Haefele, Verena
    Stojanovic, Ana
    Kittel, Maximilian
    Nolte, Hendrik
    Cerwenka, Adelheid
    Neumaier, Michael
    Schledzewski, Kai
    Sticht, Carsten
    Reiners-Koch, Philipp-Sebastian
    Goerdt, Sergij
    Geraud, Cyrill
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [56] Synergistic quorum sensing inhibition and mild-temperature photothermal therapy of integrated nanoplatform for implant-associated biofilm infections
    Jiang, Hezhong
    Fang, Wenlan
    Xu, Shiqi
    Luo, Haimeng
    Li, Dongqiu
    Liu, Yuan
    Zeng, Zhijun
    Tong, Yan
    Zhao, Long
    [J]. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2024, 663 : 143 - 156
  • [57] Cancer nanotheranostics in the second near-infrared window
    Jiang, Shanshan
    Huang, Kai
    Qu, Junle
    Lin, Jing
    Huang, Peng
    [J]. VIEW, 2021, 2 (01)
  • [58] Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics
    Jin, Mei
    Fang, Jian
    Wang, Jiao-jiao
    Shao, Xin
    Xu, Suo-wen
    Liu, Pei-qing
    Ye, Wen-cai
    Liu, Zhi-ping
    [J]. ACTA PHARMACOLOGICA SINICA, 2023, 44 (12) : 2358 - 2375
  • [59] Jin Y., 2023, J FUNCT BIOMATER, p14, 541
  • [60] Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity
    Jing, Huaqing
    Ren, Yingzi
    Zhou, Yue
    Xu, Min
    Krizkova, Sona
    Heger, Zbynek
    Lu, Qiang
    Wang, Siyu
    Liang, Xiaoyang
    Adam, Vojtech
    Li, Nan
    [J]. ACTA PHARMACEUTICA SINICA B, 2023, 13 (12) : 5030 - 5047